The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.
about
Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrateProfiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting.A data-driven method for identifying rare variants with heterogeneous trait effects.Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.A family-specific linkage analysis of blood lipid response to fenofibrate in the Genetics of Lipid Lowering Drug and Diet NetworkThe PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study.Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrateCentral obesity in males affected by a dyslipidemia-associated genetic polymorphism on APOA1/C3/A4/A5 gene cluster.Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated statesA genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome statusEffects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men.Fenofibrate and metabolic syndrome.Pharmacogenomics of lipid-lowering therapies.Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
P2860
Q28484684-CFEBF3F8-B1A7-47B0-BE97-D3FAFB32A628Q33961753-120FF172-4BAC-48C9-BE60-1D6E76B45179Q33983655-80458017-A2AE-4382-81E1-A9126C1BE8A0Q35058300-6B00CB86-2C74-4DFC-B77F-BEE225A76FFCQ35886146-B72A7368-CD94-43D7-8E09-2E5149BD576EQ36021220-4FD7F546-E338-4A62-A2DA-52DCA821DDCDQ36137264-7C17950D-9E1E-48DE-A9F4-277063F5FE0DQ36338007-7CDE8068-EAAD-4964-830D-A2E74D998A81Q36718499-48CC9566-D32B-49ED-9FAF-C767DD1C1CB2Q37109483-2CE275F2-3AAE-4BB0-944C-13FD7079472CQ37179792-1B6A1DF2-05FB-4EBE-A68F-814D00DBF582Q37183071-7F8A489B-F09B-4A1D-B072-B4A25895439AQ37463331-AC70AFCA-195B-4E2C-8DCA-020EEB9D76BFQ37612824-B37820FC-AD11-4EB5-89EF-2756C18D0BE1Q38112823-8CD85B6D-9519-4CE0-AD8A-B4B72FDE04DFQ44874088-A9085108-59D2-4060-AD92-1920195DF809
P2860
The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The genetic architecture of fa ...... onse to fenofibrate treatment.
@en
type
label
The genetic architecture of fa ...... onse to fenofibrate treatment.
@en
prefLabel
The genetic architecture of fa ...... onse to fenofibrate treatment.
@en
P2093
P2860
P50
P356
P1476
The genetic architecture of fa ...... onse to fenofibrate treatment.
@en
P2093
James M Peacock
Reagan J Kelly
Robert J Straka
P2860
P2888
P304
P356
10.1038/SJ.EJHG.5202003
P577
2008-01-23T00:00:00Z